Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000416201 | SCV000493197 | pathogenic | not provided | 2025-02-01 | criteria provided, single submitter | clinical testing | DEPDC5: PVS1, PM2, PS4:Moderate |
3billion, |
RCV003152706 | SCV003841736 | pathogenic | Epilepsy, familial focal, with variable foci 1 | 2023-02-23 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. This variant was predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported to be associated with DEPDC5 related disorder (PMID: 30093711). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. |
Gene |
RCV000416201 | SCV003915244 | pathogenic | not provided | 2022-10-13 | criteria provided, single submitter | clinical testing | Reported previously in individuals with epilepsy (Baldassari et al., 2019; Jiao et al., 2019); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: Goldhahn_2016_Abstract, 30945278, 33726816, 30093711) |
Institute of Human Genetics, |
RCV003152706 | SCV004027755 | pathogenic | Epilepsy, familial focal, with variable foci 1 | 2023-07-11 | criteria provided, single submitter | clinical testing | Criteria applied: PVS1,PS4_MOD,PM2_SUP |